Zinzani P L, Tura S, Cajozzo A, Leone G, Papa G, Gentilini P, Rossi G, Aitini E, Mandelli F
Institute of Hematology LeA Seràgnoli, Bologna, Italy.
Leuk Lymphoma. 1993;10 Suppl:39-41. doi: 10.3109/10428199309149110.
From March 1991 to April 1992, 44 previously untreated patients with stage II to IV intermediate-grade non-Hodgkin's lymphoma (according to the Kiel classification) were entered in a phase III comparative trial. The objectives of the study were to compare the efficacy and safety of using idarubicin instead of doxorubicin in the combination chemotherapeutic regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone). Forty-four patients were randomly assigned to receive either CI(idarubicin)OP or CH(doxorubicin)OP. The study is ongoing and so far no significant differences in complete response rate and (non-)hematologic toxicity have been observed.
1991年3月至1992年4月,44例先前未经治疗的Ⅱ至Ⅳ期中级非霍奇金淋巴瘤患者(根据 Kiel 分类)进入一项Ⅲ期对比试验。该研究的目的是比较在联合化疗方案CHOP(环磷酰胺、阿霉素、长春新碱、泼尼松龙)中使用伊达比星替代阿霉素的疗效和安全性。44例患者被随机分配接受CI(伊达比星)OP或CH(阿霉素)OP治疗。该研究正在进行中,迄今为止,在完全缓解率和(非)血液学毒性方面未观察到显著差异。